NAD+, NMN and NR During Pregnancy and Breastfeeding

NAD+, NMN and NR have not been established as safe wellness treatments during pregnancy or breastfeeding. Being part of normal metabolism does not establish the safety of an extra supplement, nasal spray or injection. General adult tolerability findings cannot answer questions about fetal development, transfer into milk or infant exposure.

This is a different question from whether NAD-related compounds might affect fertility. Our NMN and egg-quality review covers that research; a fertility hypothesis is not evidence that continuing a product through pregnancy is safe.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

Peter MD

Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan

See Peter MD↗

Normal NAD+ biology is not a supplement recommendation

NAD+ is essential to cellular metabolism. The body makes it through pathways involving nutrients including vitamin B3 and tryptophan. NIH's Office of Dietary Supplements describes niacin as a nutrient needed for NAD-related functions and provides nutritional recommendations for pregnancy and lactation ¹.

That does not make niacin, nicotinamide, NMN, NR and injectable NAD+ interchangeable. The ingredient, amount, route and purpose all matter. A prenatal vitamin addressing nutritional needs is not equivalent to a high-dose longevity product or a compounded injection.

If the explanation for an optional product stops at “your body already makes it,” ask what pregnancy or lactation data support the actual formulation. A biological role answers why a molecule matters in the body; it does not answer whether extra exposure benefits a pregnant person or baby.

What congenital NAD-deficiency research means

A 2017 New England Journal of Medicine paper investigated rare genetic disruptions in NAD synthesis associated with congenital malformations. Its work included affected families and experimental mouse models in which niacin supplementation could prevent malformations associated with NAD deficiency ².

This is important disease-mechanism research. It does not establish that routine NMN, NR or NAD+ wellness treatment prevents birth defects in the general population. A rare defect in a synthesis pathway is a different clinical situation from wanting more energy during pregnancy.

Related mouse research examined restricted dietary precursor availability and gene–environment interactions, finding adverse developmental outcomes when NAD supply was impaired ³. Correcting deficiency in an experimental model does not establish the safety of an unrelated consumer regimen. It also does not justify replacing a prenatal plan with a “NAD booster.”

For the distinction between ordinary nutrition and an NAD-targeted product, see foods and NAD+ precursors. Specific nutritional needs should be discussed with the clinician managing the pregnancy.

NMN and NR during pregnancy

Neither a capsule's supplement label nor a study in nonpregnant adults establishes reproductive safety. Relevant evidence would need to address the actual exposure and outcomes during pregnancy, not simply show a rise in an adult blood marker.

The National Center for Complementary and Integrative Health notes that many supplements have not been tested in pregnant or nursing people and advises discussing supplement use with a healthcare professional ⁴. That broader uncertainty is particularly relevant when a seller cites longevity research without identifying pregnancy participants.

Ask whether the proposed product has human pregnancy data, what those data measured and whether they tested the same ingredient and amount. If the answer is a mouse fertility experiment or an older-adult NMN trial, it does not resolve the question. The NMN side-effect review explains what general adult trials can tell us, while NR safety evidence addresses that separate precursor.

Breastfeeding needs its own evidence

Pregnancy and lactation are separate exposure questions. An appropriate assessment considers whether a compound or its metabolites reach milk, the amount an infant might receive and the effects of that exposure. Reassuring findings in the person taking a product would not automatically resolve infant safety.

There is no basis in the sources reviewed here for declaring a particular NAD+ wellness injection, NMN supplement or NR supplement safe for breastfeeding, or for giving a universal “pump and dump” interval. Ask the obstetric, primary-care or pediatric clinician to review the exact product rather than trying to infer a waiting period from a marketing half-life claim.

A provider's acceptance of an order is not a published lactation study. Likewise, “no problems reported” does not establish that enough breastfeeding people and infants were followed to detect problems.

Injections do not remove the uncertainty

A prescription route is not a shortcut to reproductive-safety evidence. FDA distinguishes compounded drugs from FDA-approved drugs: compounded products do not undergo the same premarket review for safety, effectiveness and quality ⁵. That distinction applies even when an ingredient is described as natural.

For a proposed NAD+ injection, ask the prescriber about the indication, the exact formulation and whether the pregnancy or breastfeeding status changes the decision. Our NAD+ injection approval guide explains the regulatory distinction. It should not be treated as a substitute for an individual clinical assessment.

If you already used a product

Write down what you took, how much, how often and by which route. Keep the label and dispensing information. Tell the clinician managing your pregnancy or breastfeeding, including any other ingredients in a blend and other medicines or supplements you use.

An exposure does not by itself prove that harm occurred. Equally, a lack of immediate symptoms cannot establish fetal or infant safety. The useful next step is an assessment of the actual exposure, rather than comparing it with an unrelated online dose or abruptly changing prescribed care without advice.

What to ask before starting or restarting

Make the purpose explicit: Is this addressing a documented nutritional issue, a medical indication or an optional wellness goal? What evidence supports it at this stage of pregnancy or lactation? Is there an established alternative for the symptom? Who will review the full ingredient list and follow up?

Our broader NAD+ guide for women covers the differences between menopause, fertility and general wellness claims. Those topics should not be combined into one assumption of safety. For pregnancy and breastfeeding, the evidence gap is itself a meaningful answer: a plausible biological benefit is not enough to recommend an optional NAD+, NMN or NR regimen.